CLEARWATER, Fla., Jan. 31, 2017 /PRNewswire/ -- Bovie Medical Corporation (NYSE MKT: BVX), provided an update on its J-Plasma® product.
The Company disclosed that it is exploring new sales channel partnerships to further scale J-Plasma® in the gynecology specialty. The pilot program with Hologic that expires at the end of February 2017 will not be extended as the two companies could not come to a mutually acceptable financial arrangement.
Additionally, the Company announced that:
- Dr. Vipul Patel, a world-renowned urologist and leader in robotic surgery, is close to completing his clinical study of J-Plasma®, with 90% of the designated patient population already enrolled. Dr. Patel is examining the benefits of using J-Plasma® for pelvic lymph node dissection. This procedure is frequently carried out to assess lymph node metastases following robotic prostatectomies and other oncological surgeries. The most common side effect of pelvic lymph node dissection is lymphocele formations, which can cause post-surgical complications requiring needle aspirations or other forms of drainage. Dr. Patel's study will determine whether more precise tools, such as J-Plasma®, could significantly reduce the formation of lymphoceles.
- Leading experts in plasma medicine at Old Dominion University published a study in the December, 2016 issue of Plasma Processes and Polymers in which cold plasma from Bovie's J-Plasma® device was shown in a laboratory model to have the potential to kill a robust strain of prostate cancer cells and inhibit their proliferation. For details of the study please click this link: http://onlinelibrary.wiley.com/doi/10.1002/ppap.201600108/epdf
The Company will release its fourth quarter and full year 2016 financial results after market on Thursday, March 9th and hold its analyst/investor conference call to discuss its financial performance and latest J-Plasma® developments on Friday morning, March 10th.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company's own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie Medical Corporation's www.boviemed.com.
SOURCE Bovie Medical Corporation
Share this article